The ENIGMA+ trial, a biorepository of ALK-rearranged NSCLC patients in order to further understand the interactions between the tumor and host immunity, is now open to researchers in this field in order to foster development of effective immune-based treatment approaches for ALK-rearranged NSCLC [75]. Here, ALK is linked to non-small cell lung carcinoma.